1. Home
  2. HPQ vs INSM Comparison

HPQ vs INSM Comparison

Compare HPQ & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo HP Inc.

HPQ

HP Inc.

HOLD

Current Price

$25.58

Market Cap

19.8B

Sector

Technology

ML Signal

HOLD

Logo Insmed Incorporated

INSM

Insmed Incorporated

HOLD

Current Price

$94.22

Market Cap

23.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HPQ
INSM
Founded
1939
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
19.8B
23.0B
IPO Year
2002
2000

Fundamental Metrics

Financial Performance
Metric
HPQ
INSM
Price
$25.58
$94.22
Analyst Decision
Hold
Strong Buy
Analyst Count
12
24
Target Price
$21.42
$201.17
AVG Volume (30 Days)
21.6M
4.2M
Earning Date
05-27-2026
05-07-2026
Dividend Yield
5.96%
N/A
EPS Growth
N/A
N/A
EPS
1.07
N/A
Revenue
$55,295,000,000.00
N/A
Revenue This Year
$3.10
$182.31
Revenue Next Year
$0.39
$65.19
P/E Ratio
$24.53
N/A
Revenue Growth
3.24
N/A
52 Week Low
$17.56
$70.57
52 Week High
$29.65
$212.75

Technical Indicators

Market Signals
Indicator
HPQ
INSM
Relative Strength Index (RSI) 57.84 27.16
Support Level $18.30 N/A
Resistance Level $26.04 $166.81
Average True Range (ATR) 1.46 4.32
MACD 0.17 0.21
Stochastic Oscillator 54.67 4.96

Price Performance

Historical Comparison
HPQ
INSM

About HPQ HP Inc.

HP (formerly Hewlett-Packard) is a behemoth in the PC and printing markets. It has focused on these markets since it exited IT infrastructure in 2015 with the split from Hewlett Packard Enterprise. HP focuses on the commercial market, but maintains sales of consumer devices and printers. The firm has a broad and global customer base, with only one third of sales coming from the US. HP completely outsources manufacturing and relies heavily on channel partners for its sales and marketing.

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.

Share on Social Networks: